CMC chemotherapy for early stage breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a chemotherapy combination (CMC) for people with early-stage, hormone receptor-positive, HER2-negative breast cancer who have a high risk of recurrence. It aims to understand if this oral regimen is effective and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage breast cancer that is hormone receptor-positive (ER or PR positive) and HER2-negative.
- You have had surgery to remove the tumor, and your most recent breast or underarm surgery was within the past 90 days.
- There is no sign that the cancer has spread to distant parts of the body.
- Your pathology report shows you have a high risk tumor based on either a gene expression test (like Oncotype DX or MammaPrint) or certain tumor features such as size, lymph node involvement, or grade.
- You have not received chemotherapy for this breast cancer before.
- You are well enough to be up and about (ECOG performance status 0, 1, or 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three older chemotherapy drugs (cyclophosphamide, methotrexate, and fluorouracil, called CMF) for adults 70 and older with breast cancer. The goal is to see if this treatment is effective and well-tolerated in this age group.
This trial tests whether it is safe to skip chemotherapy after surgery for certain patients with early-stage, hormone-receptor positive, HER2-negative breast cancer that has not spread to lymph nodes. Instead, they would receive hormone therapy plus a targeted CDK4/6 inhibitor (a pill that blocks cancer cell growth).
This Phase 1 study tests different chemotherapy approaches in people with breast cancer that has been surgically removed but is early stage. It aims to find a chemotherapy plan that’s safe and works well right after surgery.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
This trial tests a new drug combination (PCS6422 plus capecitabine) for people with advanced or metastatic breast cancer that has not responded to other treatments. The goal is to see if adding PCS6422 can make the chemotherapy work better.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.